All In Biotech

Drug Trial Radar · NCT06655246

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Last checked: Nov 21, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Jun 2029

Study completion Jun 2030

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib as current or prior therapy, or are treatment naive.

Conditions

  • Gastrointestinal Stromal Tumor (GIST)
  • Gastrointestinal Stromal Cancer
  • Gastrointestinal Stromal Neoplasm
  • Gastrointestinal Stromal Tumor, Malignant
  • Gastrointestinal Stromal Cell Tumors

Interventions

  • ziftomenibDrug

    menin inhibitor

  • imatinib mesylateDrug

    kinase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT) (Dose Expansion)Time frame: Cycle 1 (first 28 day cycle)
  2. Descriptive statistics of Adverse Events (AEs)Time frame: First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the participant is lost to follow-up, whichever comes first
  3. Clinical Benefit Rate (CBR) (Dose Escalation and Dose Expansion Cohorts A and B only)Time frame: Up to 2 years following start of treatment with ziftomenib
  4. Overall Response Rate (ORR) (Dose Expansion Cohort C)Time frame: Up to 2 years following start of treatment with ziftomenib

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Cancer Center

    Phoenix, Arizona · Recruiting

  • University of California, San Diego

    La Jolla, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • University Of California, Irvine

    Orange, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • UCLA Santa Monica Medical Center

    Santa Monica, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Sarah Cannon Research Institute

    Denver, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Cancer Center

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Harvard University

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Temple University Health System

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Dallas, Texas · Recruiting

  • University of Texas

    Houston, Texas · Recruiting

  • University of Texas Health Science Center

    San Antonio, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.